Zacks Investment Research·5d ago
Avantor Broadens RIM Single-Use Bioprocessing Reach in APACAVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Avantor's fundamental outlook is constrained by persistent revenue stagnation (0.5% YoY growth in 2026Q2) and gross margin compression from 34.1% in 2024Q2 to 31.7% in 2026Q2, reflecting pricing and mix headwinds. The company has dramatically deleveraged, with...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been flat to negative over ten quarters, with 2026Q2 growth of just 0.5% YoY, while gross margin contracted 240 basis points from 34.1% in 2024Q2 to 31.7% in 2026Q2, and operating margin fell from 10.3% to 7.2% over the same period.
The stock is considered deeply oversold with minimal downside to estimates, presenting a contrarian investment opportunity due to its undervaluation and improving fundamentals.
Avantor operates as a leading life science tools company, providing mission-critical products and services to the life sciences and advanced technology sectors.
There is material upside potential from a potential takeout, given the stock's significant drop despite only modest reductions in revenue and EPS estimates.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.21+9.7% vs $0.19 | $1.7B+5.1% vs $1.6B |
Q2 2026 Apr 29, 2026 | $0.17+8.3% vs $0.16 | $1.6B+2.5% vs $1.5B |
Q1 2026 Feb 11, 2026 | $0.22+4.8% vs $0.21 | $1.7B+1.6% vs $1.6B |
Q4 2025 Oct 29, 2025 | $0.22-2.1% vs $0.22 | $1.6B-1.3% vs $1.6B |
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock?
Benchmark AVTR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avantor, Inc. (AVTR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.94 | $10.1B | -19.15 | -3.41% | -8.09% | -9.2% | — | |
| $658.52 | $244.72B | 37.12 | 3.91% | 15.06% | 13.33% | — | |
| $221.12 | $155.44B | 43.87 | 2.9% | 15.95% | 7.66% | — | |
| $134.63 | $753.37M | 111.26 | 3.38% | 1.92% | 2.59% | — | |
| $94.39 | $4.18B | 28.01 | 3.62% | 3.41% | 9.66% | — | |
| $425.74 | $31.84B | 39.57 | 6.99% | 3.58% | 1.88% | — |
Avantor, Inc. (AVTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avantor, Inc. (AVTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 17, 2026·SEC
May 12, 2026·SEC
Get notified when AVTR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avantor, Inc. (AVTR) stock FAQ — growth, dividends, profitability & financials explained
Avantor, Inc. (AVTR) reported $6.56B in revenue for fiscal year 2025. This represents a 849% increase from $691.3M in 2016.
Avantor, Inc. (AVTR) saw revenue decline by 3.4% over the past year.
Avantor, Inc. (AVTR) reported a net loss of $578.0M for fiscal year 2025.
Avantor, Inc. (AVTR) has a return on equity (ROE) of -9.2%. Negative ROE indicates the company is unprofitable.
Avantor, Inc. (AVTR) generated $288.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
